Understanding the Market | LAEKNA-B rises over 6% again, accumulating a 36% increase over the past three trading days. Positive preliminary results from Phase I clinical MAD study
I'm PortAI, I can summarize articles.
LAEKNA-B's stock price rose over 6% again, with a cumulative increase of 36% over the past three trading days, reporting HKD 17.55 as of the time of writing, with a transaction volume of HKD 118 million. The company's LAE102 has achieved positive preliminary results in its Phase I clinical MAD study targeting obesity, showing a trend of muscle gain and fat loss. Analysts believe that bimagrumab's withdrawal from diabetes trials has weakened potential competition and enhanced LAE102's market value. DBS has reiterated a "Buy" rating, expecting subsequent data to spark interest in collaboration
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments